All In MedTech

FDA Clearance Tracker · P140026-S016

ENROUTE Transcarotid Stent System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 28, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 28, 2022

Approved

Time to decision

429 days

Received Feb 23, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P140026-S016
Device name
ENROUTE Transcarotid Stent System
Applicant location
Marborough, MA
Received
Feb 23, 2021
Decided
Apr 28, 2022
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P140026

Device type

Device class
Class III

Every decision under product code NIM

FDA's approval statement

As written in FDA's record.

Approval for the expansion of the Indications for Use to include treatment of patients at standard risk for adverse events from carotid endartectomy.

Source documents

Other decisions for Boston Scientific Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.